Drugs / LAB4
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02373995 Comparator | Feb → Jul 2015 | Graves disease | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAB4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02373995 ↗ |
| Modality | Other / unclassified | “a specifically designed probiotics (LAB4, Cultech Ltd., West Glamorgan, UK)” NCT02373995 ↗ |
| Route | Oral | “and will be administered orally, twice a day during meals, for 6 months” NCT02373995 ↗ |